Department of Physiology and Biophysics, College of Medicine, Howard University, Washington, DC 20059, USA.
Am J Physiol Heart Circ Physiol. 2013 Jun 1;304(11):H1525-37. doi: 10.1152/ajpheart.00874.2012. Epub 2013 Apr 12.
Previous studies have demonstrated positive-inotropic effects of calcitonin gene-related peptide (CGRP), but the mechanisms remain unclear. Therefore, two experiments were performed to determine the physiological correlates of the positive-inotropic effects of CGRP. Treatments designed to antagonize the effects of physiologically active CGRP₁₋₃₇ included posttreatment with CGRP₈₋₃₇ and pretreatment with LY-294002 (LY, an inhibitor of phosphatidylinositol 3-kinase), 17β-estradiol (E), and progesterone (P) were also used to modulate the effects of CGRP₁₋₃₇. Experiment 1 was in vitro studies on sarcomeres and cells of isolated adult rat cardiac myocytes. CGRP₁₋₃₇, alone and in combination with E and P, decreased sarcomere shortening velocities and increased shortening percentages, effects that were antagonized by CGRP₈₋₃₇, but not by LY. CGRP₁₋₃₇ increased resting intracellular calcium ion concentrations and Ca(2+) influxes, effects that were also antagonized by both CGRP₈₋₃₇ and LY. Experiment 2 was in vivo studies on left ventricular pressure-volume (PV) loops. CGRP₁₋₃₇ increased end-systolic pressure, ejection fraction, and velocities of contraction and relaxation while decreasing stroke volume, cardiac output, stroke work, PV area, and compliance. After partial occlusion of the vena cava, CGRP₁₋₃₇ increased the slope of the end-systolic PV relationship. CGRP₈₋₃₇ and LY attenuated most of the CGRP-induced changes. These findings suggest that CGRP-induced positive-inotropic effects may be increased by treatments with estradiol and progesterone and inhibited by LY. The physiological correlates of CGRP-induced positive inotropy observed in rat sarcomeres, cells, and intact hearts are likely to reveal novel mechanisms of heart failure in humans.
先前的研究已经证明降钙素基因相关肽(CGRP)具有正性肌力作用,但作用机制尚不清楚。因此,进行了两项实验以确定 CGRP 正性肌力作用的生理相关性。用于拮抗生理活性 CGRP₁₋₃₇作用的处理包括用 CGRP₈₋₃₇进行后处理以及用 LY-294002(LY,一种磷酸肌醇 3-激酶抑制剂)、17β-雌二醇(E)和孕酮(P)预处理,以调节 CGRP₁₋₃₇的作用。实验 1 是对分离的成年大鼠心肌细胞的肌节和细胞的体外研究。CGRP₁₋₃₇单独或与 E 和 P 联合使用时,降低肌节缩短速度并增加缩短百分比,这些作用可被 CGRP₈₋₃₇拮抗,但不能被 LY 拮抗。CGRP₁₋₃₇增加静息细胞内钙离子浓度和 Ca(2+)内流,这两种作用也可被 CGRP₈₋₃₇和 LY 拮抗。实验 2 是对左心室压力-容积(PV)环的体内研究。CGRP₁₋₃₇增加收缩末期压力、射血分数和收缩和舒张速度,同时降低每搏量、心输出量、每搏功、PV 面积和顺应性。腔静脉部分阻塞后,CGRP₁₋₃₇增加收缩末期 PV 关系的斜率。CGRP₈₋₃₇和 LY 减弱了大部分 CGRP 引起的变化。这些发现表明,用雌二醇和孕酮治疗可增加 CGRP 诱导的正性肌力作用,并被 LY 抑制。在大鼠肌节、细胞和完整心脏中观察到的 CGRP 诱导的正性肌力作用的生理相关性可能揭示人类心力衰竭的新机制。